Amalgamated Bank’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.7M | Sell |
5,384
-273
| -5% | -$64.3K | 0.01% | 907 |
|
|
2026
Q1 | $1.13M | Sell |
5,657
-30
| -0.5% | -$5.93K | 0.01% | 1013 |
|
|
2025
Q4 | $1.07M | Buy |
5,687
+52
| +0.9% | +$9.99K | 0.01% | 1036 |
|
|
2025
Q3 | $998K | Buy |
5,635
+189
| +3% | +$28.1K | 0.01% | 1063 |
|
|
2025
Q2 | $619K | Buy |
5,446
+86
| +2% | +$9.19K | ﹤0.01% | 1209 |
|
|
2025
Q1 | $564K | Sell |
5,360
-166
| -3% | -$18.8K | ﹤0.01% | 1214 |
|
|
2024
Q4 | $592K | Buy |
5,526
+177
| +3% | +$20K | ﹤0.01% | 1244 |
|
|
2024
Q3 | $535K | Buy |
5,349
+191
| +4% | +$19.2K | ﹤0.01% | 1276 |
|
|
2024
Q2 | $435K | Sell |
5,158
-148
| -3% | -$11.8K | ﹤0.01% | 1352 |
|
|
2024
Q1 | $388K | Sell |
5,306
-988
| -16% | -$72.8K | ﹤0.01% | 1407 |
|
|
2023
Q4 | $450K | Sell |
6,294
-155
| -2% | -$9.15K | ﹤0.01% | 1485 |
|
|
2023
Q3 | $386K | Sell |
6,449
-241
| -4% | -$15.9K | ﹤0.01% | 1535 |
|
|
2023
Q2 | $482K | Buy |
6,690
+12
| +0.2% | +$900 | ﹤0.01% | 1453 |
|
|
2023
Q1 | $491K | Sell |
6,678
-522
| -7% | -$37.1K | ﹤0.01% | 1433 |
|
|
2022
Q4 | $481K | Sell |
7,200
-4,342
| -38% | -$282K | ﹤0.01% | 1485 |
|
|
2022
Q3 | $620K | Sell |
11,542
-346
| -3% | -$20.3K | 0.01% | 1328 |
|
|
2022
Q2 | $662K | Buy |
11,888
+74
| +0.6% | +$4.2K | 0.01% | 1328 |
|
|
2022
Q1 | $829K | Sell |
11,814
-620
| -5% | -$45K | 0.01% | 1301 |
|
|
2021
Q4 | $1.2M | Sell |
12,434
-218
| -2% | -$20.1K | 0.01% | 1159 |
|
|
2021
Q3 | $1.1M | Sell |
12,652
-6,794
| -35% | -$525K | 0.01% | 1202 |
|
|
2021
Q2 | $1.59M | Buy |
19,446
+15,929
| +453% | +$1.33M | 0.01% | 1062 |
|
|
2021
Q1 | $334K | Sell |
3,517
-322
| -8% | -$30.4K | 0.01% | 1211 |
|
|
2020
Q4 | $238K | Buy |
3,839
+38
| +1% | +$2.17K | 0.01% | 1355 |
|
|
2020
Q3 | $226K | Sell |
3,801
-125
| -3% | -$8.53K | 0.01% | 1263 |
|
|
2020
Q2 | $274K | Sell |
3,926
-647
| -14% | -$41K | 0.01% | 1162 |
|
|
2020
Q1 | $207K | Sell |
4,573
-141
| -3% | -$7.99K | 0.01% | 1350 |
|
|
2019
Q4 | $307K | Sell |
4,714
-198
| -4% | -$13.2K | 0.01% | 1396 |
|
|
2019
Q3 | $305K | Sell |
4,912
-94
| -2% | -$5.9K | 0.01% | 1314 |
|
|
2019
Q2 | $356K | Sell |
5,006
-414
| -8% | -$30.5K | 0.01% | 1252 |
|
|
2019
Q1 | $425K | Buy |
5,420
+169
| +3% | +$12.8K | 0.01% | 1081 |
|
|
2018
Q4 | $445K | Buy |
5,251
+2,928
| +126% | +$312K | 0.01% | 984 |
|
|
2018
Q3 | $398K | Sell |
2,323
-3,154
| -58% | -$476K | 0.01% | 1023 |
|
|
2018
Q2 | $708K | Buy |
5,477
+734
| +15% | +$81.9K | 0.02% | 870 |
|
|
2018
Q1 | $489K | Sell |
4,743
-79
| -2% | -$7.81K | 0.01% | 968 |
|
|
2017
Q4 | $412K | Buy |
4,822
+298
| +7% | +$25.8K | 0.01% | 1091 |
|
|
2017
Q3 | $384K | Buy |
4,524
+16
| +0.4% | +$1.27K | 0.01% | 1068 |
|
|
2017
Q2 | $341K | Buy |
4,508
+468
| +12% | +$32.7K | 0.01% | 1124 |
|
|
2017
Q1 | $267K | Sell |
4,040
-8
| -0.2% | -$526 | 0.01% | 1214 |
|
|
2016
Q4 | $257K | Buy |
4,048
+525
| +15% | +$33.1K | 0.01% | 1236 |
|
|
2016
Q3 | $224K | Buy |
3,523
+12
| +0.3% | +$881 | 0.01% | 1196 |
|
|
2016
Q2 | $251K | Buy |
+3,511
| New | +$261K | 0.01% | 1123 |
|
Other funds holding LGND
CAM
CC
SIMG
RHJA
Amalgamated Bank's LGND Position: Q2 2026 in Review
Amalgamated Bank reduced its Ligand Pharmaceuticals (LGND) stake by 4.8% in Q2 2026, selling an estimated $64.3K and leaving 5,384 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #907.
Amalgamated Bank first reported a position in LGND in Q2 2016 and has held it in 41 quarters since. 205 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Amalgamated Bank held 5,384 shares of Ligand Pharmaceuticals worth $1.7M as of Q2 2026.
- Amalgamated Bank sold 273 Ligand Pharmaceuticals shares in Q2 2026, an estimated $64.3K.
- Ligand Pharmaceuticals made up 0.01% of Amalgamated Bank's portfolio in Q2 2026, its #907 holding.
- Amalgamated Bank first reported a position in Ligand Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- 205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.